Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022
02 11월 2022 - 9:25PM
Business Wire
Company conference call and webcast at 4:30 PM
EDT
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a
commercial-stage, cancer prevention medical diagnostics company, a
majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ),
today announced that the Company will host a business update
conference call and webcast on Monday, November 14, 2022, at 4:30
PM EDT. During the call, Lishan Aklog, M.D., Chairman, and Chief
Executive Officer, will provide a business update including an
overview of the Company’s operations and its growth strategy. In
addition, Dennis McGrath, Lucid’s Chief Financial Officer, will
discuss the Company’s third-quarter 2022 financial results.
The webcast will be available live at the investor relations
section of the Company’s website at https://ir.luciddx.com/.
Alternatively, to access the conference call by telephone,
U.S.-based listeners should dial 877-407-0789 and international
listeners should dial 201-689-8562. All listeners should provide
the operator with the conference call name “Lucid Business Update
Conference Call” to join.
Following the conclusion of the conference call, a replay will
be available for one week and can be accessed by dialing
844-512-2921 from within the U.S. or 412-317-6671 from outside the
U.S. To access the replay, all listeners should provide the
following pin number: 13732743. The webcast will be available for
replay on the investor relations section of the Company’s website
at https://ir.luciddx.com/.
About Lucid Diagnostics
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage,
cancer prevention medical diagnostics company, and subsidiary of
PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of
patients with gastroesophageal disease (GERD), also known as
chronic heartburn, who are at risk of developing esophageal
precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test,
performed on samples collected in a brief, noninvasive office
procedure with its EsoCheck® Esophageal Cell Collection Device, is
the first and only commercially available diagnostic test capable
of serving as a widespread screening tool to prevent cancer and
cancer deaths through early detection of esophageal precancer in
at-risk GERD patients. EsoGuard is commercialized in the U.S. as a
Laboratory Developed Test (LDT). EsoCheck is commercialized in the
U.S. as a 510(k)-cleared esophageal cell collection device.
EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device
designation and is the subject of multiple ongoing clinical trials.
Lucid is building nationwide direct sales and marketing teams
targeting primary care physicians, specialists, and institutions,
as well as a network of Lucid Test Centers, where at-risk GERD
patients can undergo the EsoCheck procedure for EsoGuard testing.
For more information, please visit www.luciddx.com, follow Lucid on
Twitter, and connect with Lucid on LinkedIn. For detailed
information on EsoGuard, please visit www.EsoGuard.com and follow
us on Twitter, Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements.
Forward-looking statements are any statements that are not
historical facts. Such forward-looking statements, which are based
upon the current beliefs and expectations of Lucid’s management,
are subject to risks and uncertainties, which could cause actual
results to differ from the forward-looking statements. Risks and
uncertainties that may cause such differences include, among other
things, volatility in the price of Lucid’s common stock; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required to
advance Lucid’s products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from Lucid’s clinical and preclinical studies; whether and
when Lucid’s products are cleared by regulatory authorities; market
acceptance of Lucid’s products once cleared and commercialized;
Lucid’s ability to raise additional funding as needed; and other
competitive developments. In addition, Lucid has been monitoring
the COVID-19 pandemic and the pandemic’s impact on Lucid’s
businesses. Lucid expects the significance of the COVID-19
pandemic, including the extent of its effect on its financial and
operational results, to be dictated by, among other things, the
success of efforts to contain the pandemic and the impact of such
efforts on Lucid’s businesses. These factors are difficult or
impossible to predict accurately and many of them are beyond
Lucid’s control. In addition, new risks and uncertainties may arise
from time to time and are difficult to predict. For a further list
and description of these and other important risks and
uncertainties that may affect Lucid’s future operations, see Part
I, Item 1A, “Risk Factors,” in Lucid’s most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission and
Lucid’s Registration Statement No. 333-259721 filed with the
Securities and Exchange Commission. Lucid disclaims any intention
or obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221102005588/en/
Investors and Media Adrian K.
Miller PAVmed Inc. AKM@PAVmed.com
PAVmed (NASDAQ:PAVMZ)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
PAVmed (NASDAQ:PAVMZ)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024